GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(38391)

  • GC15843 structure
    GC15843GNTI dihydrochloride
    CAS: 351183-88-5

    κ opioid receptor antagonist

  • GC15874 structure
    GC15874FIT
    CAS: 85951-63-9
    Purity: >98%

    δ-opioid agonist, irreversible

  • GC15938 structure
    GC15938β-Funaltrexamine hydrochloride
    CAS: 72786-10-8
    Purity: >95.00%

    μ opioid receptor antagonist

  • GC15982 structure
    GC15982PIK-293
    CAS: 900185-01-5
    Purity: >98.50%

    PIK-293, un anÁlogo de IC87114, es un inhibidor de PI3K, con valores de IC50 de 0,24 μM, 10 μM, 25 μM y 100 μM para p110δ, p110β, p110γ y p110α, respectivamente.

  • GC16122 structure
    GC16122Hydroxyzine
    CAS: 68-88-2
    Purity: >98%

    La hidroxizina, un agente antihistamÍnico de benzodiazepina, actÚa como un receptor de histamina H1 activo por vÍa oral y antagonista de la serotonina.

  • GC16193 structure
    GC16193ICI 174,864
    CAS: 89352-67-0
    Purity: >98%

    Selective δ opioid antagonist

  • GC16231 structure
    GC16231TG100713
    CAS: 925705-73-3
    Purity: >99.00%

    TG100713 es un inhibidor de PI3K, con IC50 de 24, 50, 165 y 215 nM para las isoformas PI3Kδ, γ, α y β respectivamente.

  • GC16434 structure
    GC16434TC-E 5006
    CAS: 1257395-14-4
    Purity: >98%

    γ-secretase modulator

  • GC16521 structure
    GC16521BW 373U86
    CAS: 155836-50-3
    Purity: >99.00%

    BW 373U86 (SNC86) es un agonista del receptor opioide δ con una IC50 de 1,49 nM.

  • GC16588 structure
    GC16588Naloxonazine dihydrochloride
    CAS: 880759-65-9
    Purity: >98%

    El diclorhidrato de naloxonazina es un antagonista especÍfico de los receptores opioides μ con una IC50 de 5,4 nM.

  • GC16833 structure
    GC16833BTB06584
    CAS: 219793-45-0
    Purity: >98%

    BTB06584 es un inhibidor de la F1Fo-ATPasa mitocondrial selectivo y dependiente de IF1 sin comprometer la sÍntesis de ATP. BTB06584 puede retrasar la muerte celular isquémica.

  • GC16872 structure
    GC16872Refametinib
    CAS: 923032-37-5
    Purity: >99.50%

    Refametinib (BAY 869766; RDEA119) es un inhibidor de MEK1/MEK2 alostérico selectivo, potente, no competitivo con ATP, disponible por vÍa oral con IC50 de 19 nM y 47 nM, respectivamente.

  • GC17031 structure
    GC17031VRT752271
    CAS: 869886-67-9
    Purity: >99.50%

    VRT752271 (BVD-523; VRT752271) es un inhibidor covalente reversible, potente, activo por v&Iacute;a oral, altamente selectivo, competitivo con ATP de las quinasas ERK1/2, con una IC50 de <0,3 nM contra ERK2. VRT752271 (BVD-523; VRT752271) inhibe el ERK2 fosforilado (pERK) y la quinasa RSK corriente abajo (pRSK) en una l&Iacute;nea celular de melanoma A375.

  • GC17109 structure
    GC17109GSK2636771
    CAS: 1372540-25-4
    Purity: >99.50%

    GSK2636771 es un potente inhibidor oral competitivo de trifosfato de adenosina de PI3Kβ, con un IC50 de 5.2 nmol/L contra la subunidad catal&iacute;tica, p110β, mientras muestra una selectividad >900 veces sobre p110α y p110γ, y >10 veces la selectividad sobre p110δ.

  • GC17388 structure
    GC17388K-Ras(G12C) inhibitor 6
    CAS: 2060530-16-5
    Purity: >98%

    El inhibidor 6 de K-Ras(G12C) es un inhibidor alost&eacute;rico irreversible de K-Ras(G12C).

  • GC17422 structure
    GC17422Pimobendan hydrochloride
    CAS: 77469-98-8
    Purity: >98%

    El clorhidrato de pimobendan (clorhidrato de UD-CG115) es un inhibidor selectivo de PDE3 con IC50 de 0,32 μM.

  • GC17553 structure
    GC17553DIPPA hydrochloride
    CAS: 155512-52-0
    Purity: >98%

    DIPPA (clorhidrato) es un antagonista de los receptores opioides κ irreversible, de larga duraci&Oacute;n, selectivo y de alta afinidad.

  • GC17677 structure
    GC17677DADLE
    CAS: 63631-40-3
    Purity: >99.50%

    δ-opioid receptor agonist

  • GC17766 structure
    GC17766BAY 80-6946 (Copanlisib)
    CAS: 1032568-63-0
    Purity: >99.50%

    BAY 80-6946 (Copanlisib) (BAY 80-6946) es un inhibidor de PI3K pan-clase I potente, selectivo y competitivo con ATP, con IC50 de 0,5 nM, 0,7 nM, 3,7 nM y 6,4 nM para PI3Kα, PI3K&88; PI3Kβ y PI3Kγ, respectivamente. BAY 80-6946 (Copanlisib) tiene una selectividad de m&Aacute;s de 2000 veces frente a otras quinasas de l&Iacute;pidos y prote&Iacute;nas, excepto mTOR. BAY 80-6946 (Copanlisib) tiene una actividad antitumoral superior.

  • GC17967 structure
    GC17967GDC-0032
    CAS: 1282512-48-4
    Purity: >99.00%

    GDC-0032 (GDC-0032) es un potente inhibidor de PI3K que se dirige a las mutaciones de PIK3CA, con Kis de 0,12 nM, 0,29 nM, 0,97 nM y 9,1 nM para PI3Kδ PI3Kα PI3K8787879847; y PI3Kβ, respectivamente.

  • GC11044 structure
    GC11044Fostamatinib (R788)
    CAS: 901119-35-5
    Purity: >98.00%

    Fostamatinib (R788) es el prof&aacute;rmaco oral del compuesto activo R406, un inhibidor de peque&ntilde;as mol&eacute;culas relativamente selectivo de Syk.

  • GC12815 structure
    GC12815Formestane
    CAS: 566-48-3
    Purity: >98.00%

    Type I steroidal aromatase inhibitor

  • GC14151 structure
    GC14151CBB1007
    CAS: 1379573-92-8
    Purity: >98%

    CBB1007 es un compuesto de amidino-guanidinio permeable a las c&eacute;lulas que act&Uacute;a como un inhibidor selectivo de LSD1 potente, reversible y competitivo con el sustrato (IC50 = 5,27 μM para hLSD1).

  • GC15259 structure
    GC15259EPZ004777 HCl
    CAS: 1380316-03-9
    Purity: >98.00%

    EPZ004777 HCl es un potente inhibidor DOT1L selectivo con una IC50 de 0,4 nM.